CJC-1295 No DAC

CAS: 863288-34-0
Molecular wt: 3367.9
Compound class: Synthetic GHRH(1-29) analogue peptide

Third-party tested. Every batch.

Independent labs test each lot before it ships. The certificates are published here, filed by batch number, for anyone to read.

Browse all COAs

CJC-1295 No DAC

CJC-1295 No DAC (modified GRF 1-29, CAS 863288-34-0) is a DPP-IV-resistant GRF(1-29) analogue without the albumin-binding maleimide that defines the DAC version — protease resistance without the multi-day carrier. Purity and identity are stated on the batch-specific COA.

CJC-1295 No DAC is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms and Conditions prior to ordering.

Description

CJC-1295 No DAC Research Standard

CJC-1295 No DAC (CAS 863288-34-0), also indexed as modified GRF(1-29), is a substituted analogue of GRF(1-29) engineered for resistance to dipeptidyl peptidase IV. The name is worth unpacking, because it describes what the molecule lacks: the Drug Affinity Complex, the maleimide group that lets the full CJC-1295 bind serum albumin. This compound keeps the protease-resistant backbone and drops the albumin carrier.^[1,2]

Mechanism of Action & Research Context

The molecular target is the growth hormone-releasing hormone receptor (GHRH-R), a class II GPCR on pituitary somatotrophs — a different receptor from the GHS-R1a targeted by the ghrelin-mimetic secretagogues.

The receptor. GHRH-R is a class II G-protein-coupled receptor required for normal growth hormone synthesis and release, and for normal growth and proliferation of pituitary somatotrophs. Mutations in mouse and human are associated with GH deficiency, short stature and pituitary hypoplasia. Alternative mRNA splicing produces variants proposed to act as dominant-negative inhibitors of the wild-type receptor.^[3]
DPP-IV is the limiting factor. GRF(1-29)NH₂ is degraded mainly by dipeptidyl peptidase IV, which clips the N-terminal dipeptide to leave inactive GRF(3-29)NH₂. Analogues designed to resist plasma DPP-IV are markedly more stable, and that resistance carries across compartments — a DPP-IV-resistant analogue was far more stable than the parent in intestinal enterocytes as well as plasma.^[2]
What “No DAC” changes. The tetrasubstituted GRF(1-29) backbone resists DPP-IV, so it survives the cleavage that inactivates sermorelin. But without the maleimide it does not conjugate to albumin, so it does not acquire the multi-day circulating presence that defines the DAC version. Substituting one for the other in an experiment changes the exposure profile substantially, not marginally.^[1,2]
No sulfur in the formula. C₁₅₂H₂₅₂N₄₄O₄₂ contains no sulfur, unlike sermorelin’s, which reflects substitution of the native Met27. That is a quick identity check against a COA.

Research Applications

Primary fields of in vitro and preclinical laboratory investigation include:

GH secretion assays in cultured anterior pituitary cells.^[1]
Comparative protease stability against unmodified GRF(1-29).^[2]
Exposure-profile comparisons against the albumin-binding DAC analogue.^[1]
Receptor pharmacology at GHRH-R.^[3]

Analytical Documentation

Purity and identity vary by manufacturing lot. Kimera Chems does not publish a single fixed purity figure for this item; refer to the batch-specific Certificate of Analysis (COA) issued for the lot received, which reflects third-party analytical testing for that lot.

References

Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. doi:10.1210/en.2004-1286
Bai JP, Chang LL. The involvement of dipeptidyl peptidase IV in brush-border degradation of GRF(1-29)NH2 by intestinal mucosal cells. J Pharm Pharmacol. 1995;47(8):698–701. doi:10.1111/j.2042-7158.1995.tb05863.x
Gaylinn BD. Growth hormone releasing hormone receptor. Recept Channels. 2002;8(3–4):155–162. PMID: 12529933.

Storage & Handling

Store at controlled room temperature, sealed and protected from light.

Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.

Related Research Compounds

Compound Class	Synthetic GHRH(1-29) analogue peptide
CAS Number	863288-34-0
Other Names	CJC1295 Without DAC, CJC1295 No DAC, CJC 1295 DAC
IUPAC Name	4-[[1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[6-amino-1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[1-[[6-amino-1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[1-[(1-amino-5-carbamimidamido-1-oxopentan-2-yl)amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoylamino]-4-oxobutanoic acid
Molecular Formula	C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight	3367.9
Lyophilised Vial Concentration	15mg, 5mg

ACE-031

Login to view price
AOD-9604

Login to view price
Arimistane

Login to view price
Bioregulators

Login to view price

Research Use Only
All products supplied by Kimera Chems LLC are intended strictly for laboratory research use. They are not drugs, dietary supplements, food, cosmetics, or veterinary products, and are not for human or animal consumption.

Regulatory Status
Kimera Chems LLC is a chemical supplier. Kimera Chems is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under Section 503B of that Act.

Intended Use and Handling
The products we offer are not intended for human use. They are intended for in-vitro and pre-clinical research purposes only. The customer acknowledges that risks exist in the handling, use, and distribution of these products, and certifies that it has the proper equipment, facilities, and personnel to manage those risks, and knowingly accepts them. These chemicals are not intended to be used, and should not be used, in inappropriate applications — including, without limitation, as food additives, drugs, cosmetics, or household chemicals, or in any application outside of in-vitro laboratory research, pre-clinical research, or laboratory chemical synthesis and materials testing.

Customer Responsibility
By purchasing these products, the customer agrees to the above. In the event the customer uses, or causes others to use, these products outside of these restrictions, the customer accepts all risk of doing so, absolves Kimera Chems of any responsibility for such actions, and agrees to indemnify and hold Kimera Chems harmless against any third-party claims arising from them.